Pulmonology

Risk Score for Asthma Exacerbation calculator

Enter the published formula inputs below to calculate and interpret this score.

Clinical inputs

Body mass index

kg/m2

Allowed range: 12–60 kg/m2

Below 30 kg/m2 is 0 points. 30 kg/m2 or higher is 14 points.

ACQ-5 score

points

Allowed range: 0–6 points

Below 1.5 is 0 points, 1.5 through just under 2.5 is 7 points, and 2.5 or higher is 13 points.

Post-bronchodilator FEV1 percent predicted

Allowed range: 10–150 %

At least 90% is 0 points, 80% through just under 90% is 13 points, and below 80% is 20 points.

Reliever occasions per day

occasions/day

Allowed range: 0–40 occasions/day

One occasion is one inhalation of terbutaline, or budesonide/formoterol used as reliever. Below 2 is 0 points, 2 through just under 4 is 11 points, and 4 or more is 26 points. The 40 occasions/day entry limit is not a printed cap.

GINA treatment step

Step 3 is 0 points and step 4 is 27 points. The table prints only these two steps.

Result

5 fields remaining

Anyone can run this calculator. Sign in to save, favourite, or send the result.

Primary source

Bateman ED et al. Development and validation of a novel risk score for asthma exacerbations: the risk score for exacerbations. J Allergy Clin Immunol. PMID: 25258144. Table II normalized score, maximum 100: BMI below 30 kg/m2 is 0 points and 30 kg/m2 or higher is 14 points. ACQ-5 below 1.5 is 0 points, 1.5 to 2.5 is 7 points, and 2.5 or higher is 13 points. Post-bronchodilator FEV1 at least 90% predicted is 0 points, 80 to 90% is 13 points, and below 80% is 20 points. Reliever use below 2 occasions per day is 0 points, 2 to 4 is 11 points, and 4 or more is 26 points. GINA step 3 is 0 points and step 4 is 27 points. A value that sits in two printed rows uses the higher row: BMI 30 kg/m2 is 14 points, ACQ-5 1.5 is 7 points, ACQ-5 2.5 is 13 points, FEV1 90% is 0 points, FEV1 80% is 13 points, 2 occasions per day is 11 points, and 4 occasions per day is 26 points. One occasion is one inhalation of terbutaline, or budesonide/formoterol used as reliever. The table prints only GINA steps 3 and 4. The paper does not print discrete risk strata inside the 0 to 100 range. (2015)

Scope: Patients aged 12 to 89 years on GINA treatment steps 3 or 4 who had at least one exacerbation in the prior year. The paper states that this score cannot be extrapolated to the wider asthma population.

Last reviewed 2026-10-17

View source

Professional use only

For qualified clinicians. Independently verify inputs, calculations, source guidance, and applicability before any clinical action. This calculator does not replace clinical judgment.

Source: Bateman ED et al. Development and validation of a novel risk score for asthma exacerbations: the risk score for exacerbations. J Allergy Clin Immunol. PMID: 25258144. Table II normalized score, maximum 100: BMI below 30 kg/m2 is 0 points and 30 kg/m2 or higher is 14 points. ACQ-5 below 1.5 is 0 points, 1.5 to 2.5 is 7 points, and 2.5 or higher is 13 points. Post-bronchodilator FEV1 at least 90% predicted is 0 points, 80 to 90% is 13 points, and below 80% is 20 points. Reliever use below 2 occasions per day is 0 points, 2 to 4 is 11 points, and 4 or more is 26 points. GINA step 3 is 0 points and step 4 is 27 points. A value that sits in two printed rows uses the higher row: BMI 30 kg/m2 is 14 points, ACQ-5 1.5 is 7 points, ACQ-5 2.5 is 13 points, FEV1 90% is 0 points, FEV1 80% is 13 points, 2 occasions per day is 11 points, and 4 occasions per day is 26 points. One occasion is one inhalation of terbutaline, or budesonide/formoterol used as reliever. The table prints only GINA steps 3 and 4. The paper does not print discrete risk strata inside the 0 to 100 range. (2015)

Ruqelo is AI and can make mistakes. Check important information.

Clinical inputs

Body mass index (kg/m2)Accepted range: 12 to 60
ACQ-5 score (points)Accepted range: 0 to 6
Post-bronchodilator FEV1 percent predicted (%)Accepted range: 10 to 150
Reliever occasions per day (occasions/day)Accepted range: 0 to 40
GINA treatment step

Primary source

View source